This perspective, marking the 30th anniversary of the Tissue Engineering journal, discusses the exciting trends in the global commercialization of tissue engineering technology. Within a historical context, we present an evolution of challenges and a discussion of the last 5 years of global commercial successes and emerging market trends, highlighting the continued expansion of the field in the northeastern United States. This leads to an overview of the last 5 years’ progress in clinical trials for tissue-engineered therapeutics, including an analysis of trends in success and failure. Finally, we provide a broad overview of preclinical research and a perspective on where the state-of-the-art lies on the horizon.
Impact Statement
This perspective, marking the 30th anniversary of the Tissue Engineering journal, discusses the exciting trends in the global commercialization of tissue engineering technology.
Get full access to this article
View all access options for this article.
References
1.
HardyJD. The first lung transplant in man (1963) and the first heart transplant in man (1964). Transplant Proc, 1999; 31(1–2):25–29.
2.
StarzlTE, MarchioroTL, Von KaullaKN, et al.Homotransplantation of the liver in humans. Surgery, Gynecology & Obstetrics, 1963; 117:659.
3.
MurrayJE, MerrillJP, HarrisonJH. Kidney transplantation between seven pairs of identical twins. Ann Surg, 1958; 148(3):343–359.
4.
BarnardCN, CooperDKC. Clinical transplantation of the heart: A review of 13 years’ personal experience. J R Soc Med, 1981; 74(9):670–674; doi: 10.1177/014107688107400910
5.
BastaniB. The present and future of transplant organ shortage: Some potential remedies. J Nephrol, 2020; 33(2):277–288.
6.
CaplanAL. Finding a solution to the organ shortage. Cmaj, 2016; 188(16):1182–1183; doi: 10.1503/cmaj.151260
7.
AbounaGM. Organ shortage crisis: Problems and possible solutions. Transplant Proc, 2008; 40(1):34–38; doi: 10.1016/j.transproceed.2007.11.067
8.
GhorbaniF, Khoddami-VishtehHR, GhobadiO, et al.Causes of family refusal for organ donation. Transplant Proc, 2011; 43(2):405–406; doi: 10.1016/j.transproceed.2011.01.031
9.
BrittbergM, LindahlA, NilssonA, et al.Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. N Engl J Med, 1994; 331(14):889–895; doi: 10.1056/NEJM199410063311401
10.
VacantiCA. The history of tissue engineering. J Cell Mol Med, 2006; 10(3):569–576.
MalcheskyPS. Artificial organs 2010: A year in review. Artif Organs, 2011; 35(3):316–350; doi: 10.1111/j.1525-1594.2011.01225.x
15.
BadwaikR. 3D printed organs: The future of regenerative medicine. Jcdr, 2019; 13(11):FE01–FE08; doi: 10.7860/JCDR/2019/42546.13256
16.
HunsbergerJ, SimonC, ZylberbergC, et al.Improving patient outcomes with regenerative medicine: How the Regenerative Medicine Manufacturing Society plans to move the needle forward in cell manufacturing, standards, 3D bioprinting, artificial intelligence-enabled automation, education, and training. Stem Cells Transl Med, 2020; 9(7):728–733; doi: 10.1002/sctm.19-0389
17.
ThomasED, StorbR. Technique for human marrow grafting. Blood, 1970; 36(4):507–515; doi: 10.1182/blood.V36.4.507.507
18.
BucknerCD, EpsteinRB, RudolphRH, et al.Allogeneic marrow engraftment following whole body irradiation in a patient with leukemia. Blood, 1970; 35(6):741–750; doi: 10.1182/blood.V35.6.741.741
19.
KumarRJ, KimbleRM, BootsR, et al.Treatment of partial-thickness burns: A prospective, randomized trial using TranscyteTM. ANZ J Surg, 2004; 74(8):622–626; doi: 10.1111/j.1445-1433.2004.03106.x
20.
ThomsonJA, Itskovitz-EldorJ, ShapiroSS, et al.Embryonic stem cell lines derived from human blastocysts. Science, 1998; 282(5391):1145–1147; doi: 10.1126/science.282.5391.1145
21.
ShamblottMJ, AxelmanJ, WangS, et al.Derivation of pluripotent stem cells from cultured human primordial germ cells. Proc Natl Acad Sci USA, 1998; 95(23):13726–13731; doi: 10.1073/pnas.95.23.13726
22.
Shin'okaT, ImaiY, IkadaY. Transplantation of a tissue-engineered pulmonary artery. N Engl J Med, 2001; 344(7):532–533; doi: 10.1056/NEJM200102153440717
23.
YuJ, VodyanikMA, Smuga-OttoK, et al.Induced pluripotent stem cell lines derived from human somatic cells. Science, 2007; 318(5858):1917–1920; doi: 10.1126/science.1151526
24.
TakahashiK, TanabeK, OhnukiM, et al.Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 2007; 131(5):861–872; doi: 10.1016/j.cell.2007.11.019
25.
AlperJ. Geron gets green light for human trial of ES cell–derived product. Nat Biotechnol, 2009; 27(3):213–214.
26.
ManleyNC, PriestCA, DenhamJ, et al.Human embryonic stem cell-derived oligodendrocyte progenitor cells: Preclinical efficacy and safety in cervical spinal cord injury. Stem Cells Transl Med, 2017; 6(10):1917–1929; doi: 10.1002/sctm.17-0065
27.
MandaiM, WatanabeA, KurimotoY, et al.Autologous induced stem-cell–derived retinal cells for macular degeneration. N Engl J Med, 2017; 376(11):1038–1046; doi: 10.1056/NEJMoa1608368
28.
TakahashiK, YamanakaS. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 2006; 126(4):663–676.
29.
GolchinA, FarahanyTZ. Biological products: Cellular therapy and FDA approved products. Stem Cell Rev Rep, 2019; 15(2):166–175; doi: 10.1007/s12015-018-9866-1
HoffmanT, KhademhosseiniA, LangerR. Chasing the paradigm: Clinical translation of 25 years of tissue engineering. Tissue Eng Part A, 2019; 25(9-10):679–687; doi: 10.1089/ten.tea.2019.0032
32.
KimYS, SmoakMM, MelchiorriAJ, et al.An overview of the tissue engineering market in the United States from 2011 to 2018. Tissue Eng Part A, 2019; 25(1-2):1–8; doi: 10.1089/ten.tea.2018.0138
33.
LysaghtMJ, ReyesJ. The growth of tissue engineering. Tissue Eng, 2001; 7(5):485–493; doi: 10.1089/107632701753213110
34.
LysaghtMJ, JaklenecA, DeweerdE. Great expectations: Private sector activity in tissue engineering, regenerative medicine, and stem cell therapeutics. Tissue Eng Part A, 2008; 14(2):305–315; doi: 10.1089/tea.2007.0267
35.
JaklenecA, StampA, DeweerdE, et al.Progress in the tissue engineering and stem cell industry “Are we there yet?” Tissue Engineering Part B: Reviews, 2012; 18(3):155–166; doi: 10.1089/ten.teb.2011.0553
36.
Anonymous. Mergent Intellect. n.d.
37.
KimbrelEA, LanzaR. Pluripotent stem cells: The last 10 years. Regen Med, 2016; 11(8):831–847; doi: 10.2217/rme-2016-0117
ZakrzewskiW, DobrzyńskiM, SzymonowiczM, et al.Stem cells: Past, present, and future. Stem Cell Res Ther, 2019; 10(1):68; doi: 10.1186/s13287-019-1165-5
40.
MartinRM, FowlerJL, CromerMK, et al.Improving the safety of human pluripotent stem cell therapies using genome-edited orthogonal safeguards. Nat Commun, 2020; 11(1):2713; doi: 10.1038/s41467-020-16455-7
41.
BoseS, KeD, SahasrabudheH, et al.Additive manufacturing of biomaterials. Prog Mater Sci, 2018; 93:45–111; doi: 10.1016/j.pmatsci.2017.08.003
42.
UllahS, ChenX. Fabrication, applications and challenges of natural biomaterials in tissue engineering. Applied Materials Today, 2020; 20:100656; doi: 10.1016/j.apmt.2020.100656
43.
HuangS, FuX. Naturally derived materials-based cell and drug delivery systems in skin regeneration. J Control Release, 2010; 142(2):149–159; doi: 10.1016/j.jconrel.2009.10.018
44.
QiuP, LiM, ChenK, et al.Periosteal matrix-derived hydrogel promotes bone repair through an early immune regulation coupled with enhanced angio- and osteogenesis. Biomaterials, 2020; 227:119552; doi: 10.1016/j.biomaterials.2019.119552
45.
ZhangX, ChenX, HongH, et al.Decellularized extracellular matrix scaffolds: Recent trends and emerging strategies in tissue engineering. Bioact Mater, 2022; 10:15–31; doi: 10.1016/j.bioactmat.2021.09.014
46.
MataiI, KaurG, SeyedsalehiA, et al.Progress in 3D bioprinting technology for tissue/organ regenerative engineering. Biomaterials, 2020; 226:119536; doi: 10.1016/j.biomaterials.2019.119536
47.
Van BelleghemS, MahadikB, SnodderlyK, et al.Dual extrusion patterning drives tissue development aesthetics and shape retention in 3d printed nipple-areola constructs. Adv Healthc Mater, 2021; 10(23):e2101249; doi: 10.1002/adhm.202101249
48.
RevahO, GoreF, KelleyKW, et al.Maturation and circuit integration of transplanted human cortical organoids. Nature, 2022; 610(7931):319–326; doi: 10.1038/s41586-022-05277-w
49.
ZushinP-JH, MukherjeeS, WuJC. FDA modernization act 2.0: Transitioning beyond animal models with human cells, organoids, and AI/ML-based approaches. J Clin Invest, n.d; 133(21):e175824; doi: 10.1172/JCI175824
50.
StraussD. Advancing Alternative Methods for Regulatory Use. 2022.
WangL, JohnsonAN. A Pragmatic approach to navigating FDA guidance for therapeutic product development in malignant hematological disease. Blood, 2023; 142(Supplement 1):7268–7268; doi: 10.1182/blood-2023-187200
